Showing 1731-1740 of 2038 results for "".
- Yale Study Uncovers How Brain Wiring Begins Before Birthhttps://modernod.com/news/yale-study-uncovers-how-brain-wiring-begins-before-birth/2482409/Researchers at Yale say they have uncovered how the brain begins to wire itself during early development, long before experiences or sensory inputs like sight come into play. The study, published this month in Science, reveals that brain cells start forming networks based on sp
- Opthea Welcomes International Retina Thought Leaders to Its Medical Advisory Boardhttps://modernod.com/news/opthea-welcomes-international-retina-thought-leaders-to-its-medical-advisory-board/2482361/Opthea announced the formation of its Medical Advisory Board, which will comprise of 10 retina thought leaders from countries around the world, including the US, Argentina, Australia, China, France, Germany, and Israel. Chaired by Arshad M. Khanani, MD, MA, FASRS, Chief Medica
- Claes H. Dohlman, MD, Cornea Research Pioneer and Visionary, Passes Away at 101https://modernod.com/news/claes-h-dohlman-md-cornea-research-pioneer-and-visionary-passes-away-at-101/2482356/Cornea Research Pioneer Claes H. Dohlman, MD, PhD, professor of Ophthalmology, Emeritus, and former Chief and Chair of the Department of Ophthalmology at Mass Eye and Ear and Harvard Medical School (HMS), passed away at the age of 101 on July 14, 2024, Mass Eye and Ear announced on Monday.
- Outlook Therapeutics Receives UK Approval of Lytenava for the Treatment of Wet AMDhttps://modernod.com/news/outlook-therapeutics-receives-uk-approval-of-lytenava-for-the-treatment-of-wet-amd/2482350/Outlook Therapeutics announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Lytenava (bevacizumab gamma), an ophthalmic formulation of bevacizumab for the treatment of wet AMD. Lytenava is the first and only aut
- Galimedix Establishes SAB in Advance of Phase 2 Study of GAL-101 for Dry AMDhttps://modernod.com/news/galimedix-therapeutics-establishes-scientific-advisory-board-in-advance-of-phase-2-study-of-gal-101-for-dry-amd/2482313/Galimedix Therapeutics has formed a Scientific Advisory Board (SAB) to provide advice and direction to the company for the development of its compound GAL-101 for the treatment of dry age-related macular degeneration (AMD). The SAB consists of retina experts from both clinical prac
- Outlook Therapeutics Receives European Authorization for Lytenava for the Treatment of Wet AMDhttps://modernod.com/news/outlook-therapeutics-receives-european-authorization-for-lytenava-bevacizumab-gamma-for-the-treatment-of-wet-amd/2482296/Outlook Therapeutics has received European Commission Marketing Authorization for Lytenava (bevacizumab gamma), an ophthalmic formulation of bevacizumab for the treatment of wet AMD. Lytenava is the first and only authorized ophthalmic formulation of bevacizumab for use in tre
- Participants of Experimental CRISPR Gene Editing Trial See Vision Improvehttps://modernod.com/news/participants-of-experimental-crispr-gene-editing-trial-see-vision-improve/2482277/About 79% of clinical trial participants experienced measurable improvement after receiving experimental, CRISPR-based gene editing that is designed to fix a rare form of blindness, according to a paper published in the New England Journal of Medicine, the National Eye Institut
- Regeneron Backs $500 Million Venture Capital Fund for Biotechnology Innovationhttps://modernod.com/news/regeneron-backs-500-million-venture-capital-fund-for-biotechnology-innovation/2482234/Regeneron Ventures announces its formation as a venture capital fund focused on promising biopharmaceutical, health care and health technology companies. The fund’s general partner will be independently managed by former Regeneron executives Jay S. Markowitz, MD, and Michael Aberman, M
- Lenz Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trialshttps://modernod.com/news/lenz-therapeutics-announces-positive-topline-data-from-phase-3-clarity-presbyopia-trials/2482207/Lenz Therapeutics announced positive topline results from its phase 3 CLARITY study of two investigational formulations of aceclidine, LNZ100 and LNZ101, for the treatment of presbyopia. In phase 3 safety and efficacy trials (CLARITY 1 and 2), our lead product candidate LNZ100 (1.75% ac
- Lucentis Biosimilar Receives Marketing Authorization from the Saudi Food & Drug Authorityhttps://modernod.com/news/lucentis-biosimilar-receives-marketing-authorization-from-the-saudi-food-drug-authority/2482156/Formycon AG and MS Pharma announced that Ravegza (FYB201), a biosimilar to Lucentis (ranibizumab), has received marketing authorization from the Saudi Food & Drug Authority. Ravegza is approved in Saudi Arabia for the treatment of patients with wet age-related macular